Skip to content

From commitments to actions: our progress in mitigating climate emissions

As a science-driven organization, Orion aligns with the scientific community’s urgent call to limit the rise in global average temperature at 1.5 degrees Celsius.

Orion Pharma has established climate targets that have been approved by the Science Based Targets initiative as being in line with the 1.5-degree target for 2030. These targets cover all three emission scopes of our value chain.

Read on to learn about the progress we have made over the years.

Scopes 1 & 2

Emission scopes 1 and 2 refer to direct greenhouse gas (GHG) emissions from Orion Pharma’s own operations and indirect emissions associated with purchased energy, respectively.

The below graph shows the development of our Scope 1 & 2 emissions since 2016.

Graph showing Orion Pharma's scope 1 & 2 emissions from 2016 to 2025

Most of the emissions generated by Orion Pharma’s own operations arise from

  • the heat used in properties and functions
  • the steam needed for maintaining process conditions (i.e., drying and heating the air)
  • electricity, which represents 45% of our total energy consumption.

Orion has committed to reducing absolute scope 1 and 2 GHG emissions by 70% by 2030 from a 2023 base year. These emissions are addressed in line with our ambitious emissions reduction roadmap through energy efficiency, process electrification, and the use of carbon-free energy as the main decarbonization levers. 

Concrete climate actions – scopes 1 & 2

We have invested in reducing our production-related emissions.

  • Flash.png

    Carbon-free electricity powers our operations

    • Since 2019, our purchased electricity has been 100% carbon-free. We purchase mainly from producers whose electricity is based on wind power, hydropower, or bioenergy. We do not consider peat to be renewable energy.
    • Our API production site in Hanko, Finland is home to a solar power plant, built in 2023 and owned and operated by our partner Oomi, which generates ~1,000 MWh of energy annually. We purchase all the electricity generated by the solar farm through a Power Purchase Agreement (PPA) to power the production of active pharmaceutical ingredients.
  • Factory 2.png

    Heat-pump plants produce carbon-free heating and cooling

    Our manufacturing facilities in Espoo and Turku, Finland are cooled and heated using the sites' AmbiHeat local heating plants and waste heat.

    Espoo:

    • Heat-pump plant introduced in 2023
    • Total heating capacity: 3 MW
    • 2,200 tCO2 emissions avoided annually
    • Need for purchased energy reduced by 55%

    Turku:

    • Heat-pump plant introduced in 2021
    • Total heating capacity: 1 MW
    • 1,000 tCO2 emissions avoided annually
    • Need for purchased energy reduced by up to 66%